Form 4: Heron Therapeutics CFO Ira Duarte Acquires 12,500 Shares Through RSU Vesting

Heron Therapeutics, Inc.'s Executive Vice President and Chief Financial Officer, Ira Duarte, acquired 12,500 shares of common stock on June 16, 2025, through the vesting and conversion of restricted stock units.

Summary

• Ira Duarte, the Executive Vice President and Chief Financial Officer of Heron Therapeutics, Inc. (HRTX), acquired 12,500 shares of the company's common stock.
• The transaction occurred on June 16, 2025.
• These shares were obtained through the exercise or conversion of Restricted Stock Units (RSUs), with a conversion price of $0 per unit.
• Each Restricted Stock Unit represents a contingent right to receive one share of common stock.
• Following this transaction, Mr. Duarte's direct beneficial ownership of common stock increased to 148,649 shares.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-arranged and scheduled event.
• Mr. Duarte still holds 25,000 unvested Restricted Stock Units.
• The Restricted Stock Units vest in four equal annual installments, commencing one year after the grant date, contingent upon Mr. Duarte's continued service to the Issuer.

Sentiment

Score: 7

Explanation: The filing reports a routine insider transaction involving the vesting of restricted stock units, which is a standard component of executive compensation. The acquisition of shares by a key executive can be viewed as a positive signal of alignment with shareholder interests, especially since it was conducted under a Rule 10b5-1 plan.

Positives

• The acquisition of shares by a key executive like the CFO can be interpreted as a positive signal of confidence in the company's future prospects.
• The transaction is a result of Restricted Stock Unit (RSU) vesting, which is a standard component of executive compensation, aligning management's financial interests with those of shareholders.
• The transaction was conducted under a Rule 10b5-1 plan, indicating a pre-planned and transparent acquisition, which helps mitigate concerns about opportunistic insider trading.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The acquisition of shares by a key executive through RSU vesting aligns management's interests with shareholders, potentially signaling confidence in the company's long-term performance.
• Employees: The RSU vesting demonstrates the company's compensation structure for executives, which can be a positive for employee morale and retention.

Next Steps

• Future vesting events for the remaining 25,000 Restricted Stock Units held by Ira Duarte, subject to his continued service to the company.

Key Dates

Recommendation

Keywords

Heron Therapeutics, HRTX, Ira Duarte, SEC Form 4, insider transaction, restricted stock units, RSU vesting, common stock, executive compensation, Rule 10b5-1 plan